Predictive Biomarkers Market Size & Share, by Indication (Cancer, Metabolic Disease, Neurological Disease); Application (Screening, Analysis, Diagnosis, Prediction, Monitoring); End-user (Hospitals, Specialty Clinics, Research Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3175
  • Published Date: Jul 28, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 – 2035

Predictive Biomarkers Market size is poised to reach USD 30 Billion by the end of 2035, growing at a CAGR of 20% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of predictive biomarkers was USD 20 Billion. The reason behind the growth is the rising prevalence of chronic diseases, such as cancer, and diabetes across the globe. Predictive biomarkers help in predicting disease progression and assessing the risk of developing certain diseases. For instance, elevated levels of below 4.0 ng/mL prostate-specific antigen in the blood can be a predictive biomarker for prostate cancer and are the most used biomarker in the management of early prostate cancer.  According to the data from the World Health Organization (WHO), over 422 million people around the world suffer from diabetes, and it causes about 1.6 million deaths every year, whereas cancer caused over 10 million deaths in 2020.

The growing geriatric population is believed to fuel the market growth since older populations are more prone to diseases such as cardiovascular disease, and also cancer. Hence, the demand for predictive biomarkers is expected to increase to diagnose age-related conditions. According to World Health Organization, the number of people 60 and older in the world is expected to double (2.1 billion) by 2050.

Predictive Biomarkers Market
Get more information on this report: Request Free Sample PDF

Predictive Biomarkers Sector: Growth Drivers and Challenges

Growth Drivers

  • Expanding Use of Biomarkers for Diagnostic Purposes– The use of biomarkers in numerous sectors, such as personalized medicine, companion diagnostics, disease risk assessment, and drug development, is expected to drive market growth. Predictive biomarkers assist in determining the likelihood of an adverse reaction to a specific treatment modality, its early diagnosis, and its severity. The use of predictive biomarkers might drastically lower healthcare costs since they anticipate whether a given medication will be effective or not, which gives them an edge over predisposition biomarkers.
  • Growing Demand for Personalized Medicine- Numerous scientific breakthroughs, and increased demand for the discovery of novel drugs, have led to the rise of personalized medicine. This has significantly driven market growth. Biomarkers are crucial instruments that help in personalizing medical treatments to individual patients which means providing the right treatment to the right patient, at the right dose, at the right time.


  • Lack of Efficient Regulatory and Reimbursement Systems- The regulatory and reimbursement processes in the majority of OECD nations are not well suited to handle this new influx of biomarker-based diagnostic tests. Modern biomarker-based diagnostics that produce complex data needing in-depth analysis and interpretation are not well adapted to the regulatory systems now in place as they were designed around simple diagnostic tests. The adoption of these technologies in the clinical arena may be hampered by inadequately designed regulatory and reimbursement systems, which may also serve as a deterrent to further biomarker research. The processes for requesting approval and/or compensation are still being developed at this time.
  • High Capital Investment
  • Technical Difficulties with Collecting and Storing Samples

Predictive Biomarkers Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 20 Billion

Forecast Year Market Size (2035)

~ USD 30 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Predictive Biomarkers Segmentation

Application (Screening, Analysis, Diagnosis, Prediction, Monitoring)

The prediction segment in the predictive biomarkers market is estimated to gain a robust revenue share in the coming years owing to rising demand for measuring the likelihood of results of any treatment procedure. Predictive biomarkers are frequently employed at all stages of the drug discovery and development process to show the connection between the biomarker and treatment outcome and determine whether a disease or condition is present. Owing to their ability to predict whether a patient will respond to a specific chemotherapy, predictive biomarkers aid in the optimization of treatment choices, and are highly used to forecast the effects of treatment on patients, which helps medical professionals to provide specific medications.

End-Use (Hospitals, Specialty Clinics, Research Institutes)

The research institutes segment in the predictive biomarkers market is set to garner a notable share shortly driven by the investment made by various key market players for the creation of novel biomarkers for diagnostic and therapeutic purposes, along with large-scale funds from the government and private organizations which have been given to groups working on the development of new drugs. Research centers contribute to advancements in technology that facilitate biomarker identification associated with specific diseases. Besides this, they conduct clinical trials to assess the utility of predictive biomarkers and promote awareness regarding the benefits of these biomarkers.

Our in-depth analysis of the global market includes the following segments:


  • Cancer
  • Metabolic Disease
  • Neurological Disease


  • Screening
  • Analysis
  • Diagnosis
  • Prediction
  • Monitoring


  • Hospitals
  • Specialty Clinics
  • Research Institutes

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Predictive Biomarkers Industry- Regional Synopsis

North American Market Forecast

Predictive biomarkers market in North America is predicted to account for the largest share of 35% by the end of 2035 backed by the advanced research and development activities in the healthcare sector. The U.S. healthcare industry benefits from an effective system of medical research and development and invests significantly in the creation of new diagnostic instruments, which is predicted to spur market expansion. These efforts can lead to the creation of new predictive biomarkers and also increase their availability & accessibility in the region.

APAC Market Statistics

The Asia Pacific Predictive Biomarkers market is estimated to be the second largest, during the forecast timeframe led by increasing spending in healthcare. For instance, health-related spending per person is higher in Australia, Japan, and Singapore, which has led to a rise in the awareness of early disease diagnosis among people living in those countries.

Predictive biomarkers are becoming more widely used in the area as a result, as they aid in disease prevention and early intervention. In Singapore, it is anticipated that by 2030, public and private spending on aged healthcare will increase to over USD 48 billion.

Research Nester
Predictive Biomarkers Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Predictive Biomarkers Landscape

    • Siemens Healthcare GmbH
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • F. Hoffmann-La Roche Ltd
    • Epigenomics AG
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • QIAGEN GmbH
    • Danaher Corporation
    • Biomarker Technologies, Inc.
    • Almac Group Limited
    • Myriad Genetics, Inc.
    • Meso Scale Diagnostics, LLC

In the News

  • Myriad Genetics to join hands with Intermountain Precision Genomics to produce genetic testing devices for the global market.
  • The Centre for Ocular Research & Education (CORE) and Meso Scale Diagnostics, LLC announced the initiative to use the Meso Scale Discovery platform to identify biomarkers.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3175
  • Published Date: Jul 28, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising prevalence of chronic diseases, such as cancer, and diabetes across the globe and the growing geriatric population are the major factors driving the growth of the market.

The market size of Predictive Biomarkers is anticipated to attain a CAGR of 20% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Biomarker Technologies, Inc., Almac Group Limited, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, and others.

The research institutes segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Predictive Biomarkers Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying